Core Insights - Scholar Rock reported its financial results for Q3 2025, focusing on advancements in treatments for spinal muscular atrophy (SMA) and other neuromuscular diseases [1] Financial Performance - The company provided an update on its financial results for the third quarter ended September 30, 2025, indicating ongoing progress in its financial metrics [1] Company Developments - Scholar Rock emphasized its commitment to improving the lives of individuals with SMA and other rare neuromuscular diseases through its innovative platform in myostatin biology [1]